AstraZeneca’s Farxiga Fails To Get FDA OK As Insulin Supplement In Type 1 Diabetes

The UK pharma said the FDA had issued a complete response letter, declining its application for using Farxiga in the new T1D indication. Analysts suspect worries over diabetic ketoacidosis risk lie behind the rejection.

Laptop
The FDA’s CRL will have said the Farxiga application cannot be approved in its present form • Source: Shutterstock

AstraZeneca PLC on 5 July said the US Food and Drug Administration declined to approve its diabetes treatment Farxiga as a supplement to insulin in adults with type 1 diabetes, fanning fresh doubts about use of SGLT2 inhibitors as a treatment for the condition.

In a tersely worded statement, AstraZeneca said it had received a complete response letter from the FDA in reply to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip